Identa (IDTA) AI Stock Analysis

Identa

(Other OTC:IDTA)

Select Model

Rating:64Neutral

Price Target:$0.38▲(7.14% Upside)

Action:reiterated

Date:10/14/26

The score is led by improving financial performance (better profitability and reduced leverage), but is held back by historically inconsistent cash flow and earnings/revenue volatility. Technicals show an uptrend, yet overbought signals raise near-term pullback risk. Valuation is supportive given the low P/E.

Positive Factors

Improved profitability and growthThe recent rebound in revenue and profitability indicates improved operating performance, with gross, operating, and net margins all at meaningful levels. If maintained, this stronger earnings base can support reinvestment and improve the company’s ability to fund operations over the next several quarters.

Negative Factors

Unreliable cash-flow historyThe shift from negative operating cash flow in multiple prior years to positive TTM generation shows that cash conversion has not been dependable through the cycle. This variability can make internally funded investment, debt reduction, and other capital-allocation decisions less predictable over the next several quarters.

Identa (IDTA) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $1.42M
Dividend Yield: ―
Average Volume (3M): 2,284
Price to Earnings (P/E): 9.8
Beta (1Y): -1.37
Revenue Growth: 57.25%
EPS Growth: ―
Country: US
Employees: 14
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Identa Business Overview & Revenue Model

Company Description

IDenta Corp. operates as a detection and forensic science company. The company offers drug testing kits, explosives testing kits, aero chamber sniffer, forensic, urine drug testing, and saliva drug testing products. It provides its solutions to law e...

How the Company Makes Money

null

Identa Financial Statement Overview

Summary

TTM fundamentals show improvement (revenue up ~10%, gross margin ~53%, operating margin ~14%, net margin ~11%) and leverage has moderated (debt-to-equity ~0.66 with strong ROE ~22%). Offsetting this, multi-year results show uneven revenue/margin trends and inconsistent cash generation (negative operating cash flow in 2021 and 2023), reducing confidence in durability.

Income Statement

74Positive

Balance Sheet

67Positive

Cash Flow

58Neutral

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.86M	1.34M	1.46M	1.05M	1.34M	1.39M
Gross Profit	958.46K	686.57K	756.46K	662.98K	983.39K	1.02M
EBITDA	254.66K	128.96K	328.40K	57.13K	199.56K	135.57K
Net Income	141.05K	99.04K	258.34K	14.64K	162.71K	69.18K
Balance Sheet
Total Assets	2.38M	1.92M	1.66M	1.53M	1.56M	1.23M
Cash, Cash Equivalents and Short-Term Investments	669.76K	379.42K	735.95K	264.29K	368.90K	347.15K
Total Debt	661.18K	645.20K	640.23K	785.37K	820.28K	511.63K
Total Liabilities	1.08M	1.04M	921.01K	1.01M	1.10M	799.32K
Stockholders Equity	1.30M	879.16K	742.31K	516.12K	459.63K	430.01K
Cash Flow
Free Cash Flow	253.53K	40.28K	555.85K	-151.97K	61.56K	-221.97K
Operating Cash Flow	284.25K	56.94K	561.89K	-137.63K	94.31K	-88.95K
Investing Cash Flow	-87.01K	-48.05K	-260.40K	-8,154	-8,611	-133.02K
Financing Cash Flow	276.22K	-43.78K	-151.47K	-23.53K	-63.95K	28.02K

Identa Technical Analysis

Technical Analysis SentimentPositive

Last Price0.35

Price Trends

50DMA0.33Positive

100DMA0.28Positive

200DMA0.24Positive

Market Momentum

MACD0.01Positive

RSI79.73Negative

STOCH55.56Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDTA, the sentiment is Positive. The current price of 0.35 is above the 20-day moving average (MA) of 0.34, above the 50-day MA of 0.33, and above the 200-day MA of 0.24, indicating a bullish trend. The MACD of 0.01 indicates Positive momentum. The RSI at 79.73 is Negative, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDTA.

Identa Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IDTA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IDTA	64Neutral	$1.42M	9.83	14.16%	―	57.25%	―
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BNBX	47Neutral	$573.24K	-0.00	-337.10%	―	-27.39%	99.29%
BIAF	43Neutral	$3.73M	-0.02	-257.27%	―	-23.17%	67.18%
NDRA	34Underperform	$7.12M	-0.76	-224.80%	―	―	98.17%
INBS	31Underperform	$5.84M	-0.17	-170.36%	―	38.09%	54.22%

* Healthcare Sector Average

Performance Comparison

IDTA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IDTA	Identa Corp	0.35	0.18	107.10%
BNBX	Bnb Plus Corp.	0.09	-3.32	-97.45%
NDRA	Endra Life Sciences	4.80	-0.19	-3.81%
INBS	Intelligent Bio Solutions Inc.	1.66	-6.77	-80.31%
BIAF	bioAffinity Technologies, Inc.	2.99	-28.36	-90.46%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 14, 2026

Identa AI Stock Analysis